About
Proxi Biotech develops novel toxoid-based active immunotherapies to address bacterial re-infections caused by drug-resistant pathogens, targeting antimicrobial resistance and recurrent infections such as Clostridium difficile and urinary tract infections.
Explore Proxi Biotech's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.